Clinical Trials Logo

ALK Fusion Protein Expression clinical trials

View clinical trials related to ALK Fusion Protein Expression.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02587650 Terminated - Clinical trials for ALK Fusion Protein Expression

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Start date: March 26, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.